GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Shiller PE Ratio

Trillium Therapeutics (Trillium Therapeutics) Shiller PE Ratio : (As of May. 12, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Trillium Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Trillium Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Shiller PE Ratio Chart

Trillium Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Trillium Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Trillium Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Trillium Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trillium Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trillium Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Trillium Therapeutics's Shiller PE Ratio falls into.



Trillium Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Trillium Therapeutics's E10 for the quarter that ended in Sep. 2021 is calculated as:

For example, Trillium Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2021 (Change)*Current CPI (Sep. 2021)
=-0.18/115.7343*115.7343
=-0.180

Current CPI (Sep. 2021) = 115.7343.

Trillium Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201112 -2.337 95.213 -2.841
201203 -0.601 96.783 -0.719
201206 -0.590 96.819 -0.705
201209 -0.610 97.633 -0.723
201212 0.019 96.871 0.023
201303 -0.590 98.209 -0.695
201306 -0.855 98.518 -1.004
201309 -0.872 98.790 -1.022
201312 -0.350 98.326 -0.412
201403 -0.452 99.695 -0.525
201406 -0.928 100.560 -1.068
201409 -0.538 100.428 -0.620
201412 -0.772 99.070 -0.902
201503 -0.773 99.621 -0.898
201506 -0.644 100.684 -0.740
201509 -0.156 100.392 -0.180
201512 -0.229 99.792 -0.266
201603 -0.709 100.470 -0.817
201606 -0.750 101.688 -0.854
201609 -0.768 101.861 -0.873
201612 -0.807 101.863 -0.917
201703 -1.095 102.862 -1.232
201706 -1.023 103.349 -1.146
201709 -0.846 104.136 -0.940
201712 -0.627 104.011 -0.698
201803 -0.503 105.290 -0.553
201806 -0.700 106.317 -0.762
201809 -0.704 106.507 -0.765
201812 -0.423 105.998 -0.462
201903 -0.460 107.251 -0.496
201906 -0.180 108.070 -0.193
201909 -0.340 108.329 -0.363
201912 -0.220 108.420 -0.235
202003 -0.250 108.902 -0.266
202006 -0.280 108.767 -0.298
202009 -0.140 109.815 -0.148
202012 -0.040 109.897 -0.042
202103 -0.110 111.754 -0.114
202106 -0.180 114.631 -0.182
202109 -0.180 115.734 -0.180

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Trillium Therapeutics  (NAS:TRIL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Trillium Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Trillium Therapeutics (Trillium Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

Trillium Therapeutics (Trillium Therapeutics) Headlines